Eribulin mesylate exerts antitumor effects via CD103.
Oya K, Nakamura Y, Watanabe R, Tanaka R, Ichimura Y, Kubota N, Matsumura Y, Tahara H, Okiyama N, Fujimoto M, Nomura T, Fujisawa Y.
Oya K, et al. Among authors: fujisawa y.
Oncoimmunology. 2023 May 27;12(1):2218782. doi: 10.1080/2162402X.2023.2218782. eCollection 2023.
Oncoimmunology. 2023.
PMID: 37261089
Free PMC article.